Buffalo, NY (PRWEB) September 28, 2022 A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen
A therapy made of immune system T cells engineered to target a somewhat enigmatic cell protein called GPRC5D antigen produced impressive results in its first clinical trial in patients with multiple myeloma, researchers at Memorial Sloan Kettering Cancer Center (MSK), Dana-Farber Cancer Institute and Roswell Park Comprehensive Cancer Center report in a new study published today by the New England Journal of Medicine.